Michael R. Migden
The University of Texas MD Anderson Cancer Center(US)
Publications by Year
Research Areas
Nonmelanoma Skin Cancer Studies, Hedgehog Signaling Pathway Studies, Cancer and Skin Lesions, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma(2012)1,419 cited
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial(2020)462 cited
- → Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial(2015)423 cited
- → Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study(2017)407 cited
- → Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma(2015)384 cited
- → Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial(2021)268 cited
- → Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC(2015)207 cited
- → Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study(2017)190 cited
- → Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study(2019)185 cited